NO20030761L - Farmasöytisk kombinasjon av angiotensin II antagonister og angiotensin I konverterende enzyminhibitorer - Google Patents
Farmasöytisk kombinasjon av angiotensin II antagonister og angiotensin I konverterende enzyminhibitorerInfo
- Publication number
- NO20030761L NO20030761L NO20030761A NO20030761A NO20030761L NO 20030761 L NO20030761 L NO 20030761L NO 20030761 A NO20030761 A NO 20030761A NO 20030761 A NO20030761 A NO 20030761A NO 20030761 L NO20030761 L NO 20030761L
- Authority
- NO
- Norway
- Prior art keywords
- angiotensin
- antagonist
- antagonists
- converting enzyme
- mediated effects
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title abstract 4
- 229940123413 Angiotensin II antagonist Drugs 0.000 title abstract 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- 102400000967 Bradykinin Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Oppfinnelsen angår en metode for behandling av indikasjoner som positivt kan påvirkes ved hemning av AT-medierte effekter med opprettholdelse av AT-reseptor medierte effekter av Angiotensin II og ved ACE-hemning, for således også å øke bradykinin-medierte effekter, f. eks. for å redusere forekomst av slag, akutt myokardialt infarkt eller kardiovaskulær død eller av indikasjoner forbundet med økning av ATreseptorer i subepitel-området eller økning av AT-reseptorer i epitelet, omfattende samadministrering av effektive mengder av en Angiotensin II-antagonist og en ACE-inhibitor, farmasøytiske preparater inneholdende en Angiotensin II- antagonist sammen med en ACE-inhibitor og anvendelse av en Angiotensin II antagonist og en ACE-inhibitor for fremstilling av tilsvarende farmasøytiske preparater.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0020691.2A GB0020691D0 (en) | 2000-08-22 | 2000-08-22 | Pharmaceutical combination |
| DE10108215A DE10108215A1 (de) | 2000-08-22 | 2001-02-20 | Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym |
| PCT/EP2001/009428 WO2002015891A2 (en) | 2000-08-22 | 2001-08-16 | Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| CA002372785A CA2372785A1 (en) | 2000-08-22 | 2002-02-21 | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| JP2002093288A JP2003238444A (ja) | 2000-08-22 | 2002-02-21 | アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20030761D0 NO20030761D0 (no) | 2003-02-18 |
| NO20030761L true NO20030761L (no) | 2003-02-18 |
Family
ID=32234234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030761A NO20030761L (no) | 2000-08-22 | 2003-02-18 | Farmasöytisk kombinasjon av angiotensin II antagonister og angiotensin I konverterende enzyminhibitorer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20030171415A1 (no) |
| EP (1) | EP1313468A2 (no) |
| JP (1) | JP2003238444A (no) |
| CN (1) | CN1447691A (no) |
| AU (1) | AU2001295465B2 (no) |
| BG (1) | BG107558A (no) |
| BR (1) | BR0113321A (no) |
| CA (2) | CA2415788A1 (no) |
| CZ (1) | CZ2003534A3 (no) |
| DE (1) | DE10108215A1 (no) |
| GB (1) | GB0020691D0 (no) |
| IL (1) | IL153937A0 (no) |
| NO (1) | NO20030761L (no) |
| SK (1) | SK2062003A3 (no) |
| WO (1) | WO2002015891A2 (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| HUP0203326A3 (en) * | 1999-08-30 | 2003-04-28 | Sanofi Aventis Deutschland | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| US20040157911A1 (en) * | 1999-08-31 | 2004-08-12 | Spiridon Spireas | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
| US20040248968A1 (en) * | 2002-02-20 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| US9029363B2 (en) * | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
| US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
| US20040265238A1 (en) | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| SE0302331D0 (sv) * | 2003-08-29 | 2003-08-29 | Astrazeneca Ab | New use II |
| DE102004008804A1 (de) * | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mehrschichttablette |
| WO2005097109A1 (en) * | 2004-04-01 | 2005-10-20 | Daniel Batlle | Methods for achieving a protective ace2 expression level |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| EP1723962A1 (en) | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
| US8080534B2 (en) * | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| WO2009087116A1 (en) * | 2008-01-11 | 2009-07-16 | Novartis Ag | Use of spp100 for the treatment of acute mi |
| PE20091809A1 (es) | 2008-04-17 | 2009-12-03 | Sanofi Aventis | Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad |
| EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
| CN101869710A (zh) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | 降压药物组合物 |
| US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
| US20140170158A1 (en) * | 2012-12-17 | 2014-06-19 | The Johns Hopkins University | Compositions and methods for treating or preventing lung diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821232A (en) * | 1990-05-11 | 1998-10-13 | Pfizer Inc. | Synergistic therapeutic compositions and methods |
| EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
| WO1996031234A1 (en) * | 1995-04-07 | 1996-10-10 | Novartis Ag | Combination compositions containing benazepril or benazeprilat and valsartan |
| CA2224451A1 (en) * | 1995-06-30 | 1997-01-23 | Merck & Co., Inc. | Method of treating renal disease using an ace inhibitor and an aii antagonist |
| ATE216881T1 (de) * | 1996-06-24 | 2002-05-15 | Merck & Co Inc | Zusammensetzung auf basis von enalapril und losartan |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| HUP0203326A3 (en) * | 1999-08-30 | 2003-04-28 | Sanofi Aventis Deutschland | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
-
2000
- 2000-08-22 GB GBGB0020691.2A patent/GB0020691D0/en not_active Ceased
-
2001
- 2001-02-20 DE DE10108215A patent/DE10108215A1/de not_active Withdrawn
- 2001-08-16 BR BR0113321-7A patent/BR0113321A/pt not_active IP Right Cessation
- 2001-08-16 AU AU2001295465A patent/AU2001295465B2/en not_active Ceased
- 2001-08-16 WO PCT/EP2001/009428 patent/WO2002015891A2/en not_active Ceased
- 2001-08-16 SK SK206-2003A patent/SK2062003A3/sk not_active Application Discontinuation
- 2001-08-16 EP EP01976082A patent/EP1313468A2/en not_active Ceased
- 2001-08-16 IL IL15393701A patent/IL153937A0/xx unknown
- 2001-08-16 CA CA002415788A patent/CA2415788A1/en not_active Abandoned
- 2001-08-16 CZ CZ2003534A patent/CZ2003534A3/cs unknown
- 2001-08-16 CN CN01814414A patent/CN1447691A/zh active Pending
-
2002
- 2002-02-21 JP JP2002093288A patent/JP2003238444A/ja active Pending
- 2002-02-21 CA CA002372785A patent/CA2372785A1/en not_active Abandoned
-
2003
- 2003-01-30 US US10/354,713 patent/US20030171415A1/en not_active Abandoned
- 2003-02-14 BG BG107558A patent/BG107558A/bg unknown
- 2003-02-18 NO NO20030761A patent/NO20030761L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1447691A (zh) | 2003-10-08 |
| CZ2003534A3 (cs) | 2003-06-18 |
| AU2001295465B2 (en) | 2007-12-13 |
| WO2002015891A3 (en) | 2002-06-13 |
| BG107558A (bg) | 2004-01-30 |
| US20030171415A1 (en) | 2003-09-11 |
| JP2003238444A (ja) | 2003-08-27 |
| DE10108215A1 (de) | 2002-08-22 |
| BR0113321A (pt) | 2003-07-15 |
| SK2062003A3 (en) | 2003-08-05 |
| NO20030761D0 (no) | 2003-02-18 |
| GB0020691D0 (en) | 2000-10-11 |
| EP1313468A2 (en) | 2003-05-28 |
| WO2002015891A2 (en) | 2002-02-28 |
| IL153937A0 (en) | 2003-07-31 |
| CA2372785A1 (en) | 2003-08-21 |
| AU9546501A (en) | 2002-03-04 |
| CA2415788A1 (en) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0113321A (pt) | Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i | |
| WO2004047735A3 (en) | Broad spectrum anti-viral therapeutics and prophylaxis | |
| EA200100937A1 (ru) | Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов | |
| EA200100936A1 (ru) | Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов | |
| NO20005155L (no) | Forbedring av antistoff-cytokin fusjon protein-medierte immunoresponser ved ko-administrasjon med angiogeneseinhibator | |
| BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
| TR200100472T2 (tr) | Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler | |
| EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
| DE60142921D1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
| EA200000433A1 (ru) | Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы | |
| CU22997A3 (es) | Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización | |
| ATE250931T1 (de) | Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden | |
| PT1185649E (pt) | Promotor do gene da miostatina e inibicao da sua activacao | |
| WO2005084654A3 (en) | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents | |
| MX2011009852A (es) | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. | |
| AU2001230395A1 (en) | Use of cox-2 inhibitors as gastroprokinetics | |
| MXPA06001828A (es) | Metodo para el tratamiento y bioensayo que involucra el factor de inhibicion de migracion de macrofagos ("mif"), como un factor de depresion del miocardio, derivado del corazon. | |
| EA200100951A1 (ru) | Комбинированная терапия ингибитором ангиотензинпревращающего фермента и эпоксистероидным антагонистом альдостерона для лечения сердечно-сосудистого заболевания | |
| EA200201149A1 (ru) | Фармацевтические композиции и способы для предотвращения рецидива мигрени | |
| IL133179A0 (en) | Compositions and methods for inhibiting nematocyst discharge | |
| AR026901A1 (es) | Peptidos con n-alquilacion que tienen actividad antiangiogenica | |
| PT1292290E (pt) | Composicoes farmaceuticas que compreendem derivados de acriloil-distamicina e inibidores de topoisomerase 1 e ii | |
| YU12703A (sh) | Farmaceutska kombinacija antagonista angiotenzina ii i inhibitora angiotenzin i konvertujućeg enzima | |
| NO20054216L (no) | Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag | |
| AU2001252419A1 (en) | Thrombin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |